Interactive inhibitory effects of formoterol and montelukast on activated human neutrophils

European Respiratory Journal

Volumn 36, Issue 6, 2010, Pages 1417-1424

  Gravett, C M ^a,b   Theron, A J ^a,b   Steel, H C ^a,b   Tintinger, G R ^a,b   Cockeran, R ^a,b   Feldman, C ^c,d   Anderson, R ^b  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Calcium; Cyclic AMP; Elastase; Neutrophils; Superoxide

Indexed keywords

BETA2 INTEGRIN; CALCIUM ION; CORTICOSTEROID DERIVATIVE; CYCLIC AMP; CYTOCHALASIN B; ELASTASE; FORMOTEROL; FORMYLMETHIONYLLEUCYLPHENYLALANINE; LEUKOTRIENE B4; MONTELUKAST; SALBUTAMOL; SUPEROXIDE; THROMBOCYTE ACTIVATING FACTOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ISOLATION; DRUG EFFECT; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; HUMAN; HUMAN CELL; LEUKOCYTE ACTIVATION; NEUTROPHIL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS;

EID: 78649756979     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00157409     Document Type: Article

References (32)

1. McFadden ER. Inhaled glucocorticoids and acute asthma: therapeutic breakthrough or non-specific effect? Am J Respir Crit Care Med 1998; 157: 677-678.
2. Van Weel C, Bateman ED, Bousquet J, et al. Asthma management pocket reference 2008. Allergy 2008; 63: 997-1004.
3. 2-adrenergic receptor function, response and regulation. J Allergy Clin Immunol 2006; 117: 18-24.
4. 2-agonists on resident and infiltrating inflammatory cells. J Allergy Clin Immunol 2002; 110: Suppl., S282-S290.
5. 2-agonists in primary lung epithelial cells is independent of glucocorticoid receptor. Eur Respir J 2007; 30: 848-856.
6. Barnes PJ. New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin Immunol 2007; 119: 1055-1062.
7. Capra V, Ambrosio M, Riccioni G, et al. Cysteinyl-leukotriene receptor antagonists: present situation and future opportunities. Curr Med Chem 2006; 13: 3213-3216.
8. Tintinger GR, Theron AJ, Anderson R, et al. Comparison of the effects of selective and non-selective β-adrenergic agonists on the pro-inflammatory activities of human neutrophils in vitro. Inflammation 2000; 24: 239-249.
9. Anderson R, Theron AJ, Gravett CM, et al. Montelukast inhibits neutrophil pro-inflammatory activity by a cyclic AMP-dependent mechanism. Br J Pharmacol 2009; 156: 105-115.
10. 4 sensitize human neutrophils for hyperreactivity to chemoattractants. Inflamm Res 2009; 58: 263-268.
11. MacDowell AL, Peters SP. Neutrophils in asthma. Curr Allergy Asthma Rep 2007; 7: 464-468.
12. Moore AR, Willoughby DA. The role of cAMP regulation in controlling inflammation. Clin Exp Immunol 1995; 101: 387-389.
13. Wang P, Wu P, Ohleth KM, et al. Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol 1999; 56: 170-174.
14. Knorr B, Holland S, Schwartz J, et al. Clinical pharmacology of montelukast. Clin Exp Allergy Rev 2001; 1: 254-260.
15. Farr SJ, Rowe AM, Rubsamen R, et al. Aerosol deposition in the human lung following administration from a microprocessor controlled pressurized metered dose inhaler. Thorax 1995; 50: 639-644.
16. 2+ indicators with greatly improved fluorescent properties. J Biol Chem 1985; 260: 3440-3450.
17. Dal Negro RW, Borderias L, Zhang Q, et al. Rates of asthma attacks in patients with previously inadequately controlled mild asthma treated in clinical practice with combination drug therapy: an exploratory post-hoc analysis. BMC Pulm Med 2009; 9: 10.
18. Currie GP, Lee DKC, Dempsey OJ, et al. A proof of concept study to evaluate putative benefits of montelukast in moderate persistent asthmatics. Br J Clin Pharmacol 2003; 55: 609-615.
19. Dempsey OJ, Wilson AM, Sims EJ, et al. Additive bronchoprotective effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids. Chest 2000; 117: 950-953.
20. 2-agonists: addition of montelukast in an open-label pilot study. Curr Med Res Opin 2005; 21: 863-869.
21. Korn D, Van den Brande P, Potvin E, et al. Efficiency of add-on montelukast in patients with non-controlled asthma: a Belgian open-label study. Curr Med Res Opin 2009; 25: 489-497.
22. 2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial). Can Respir J 2009; 16: 17-24.
23. Mak JC, Chan-Yeung MM. Reactive oxidant species in asthma. Curr Opin Pulm Med 2006; 12: 7-11.
24. 1 secretion in human airway smooth muscle. Am J Respir Cell Mol Biol 2006; 35: 407-414.
25. Ohnishi H, Miyahara N, Gelfand EW. The role of leukotriene B4 in allergic diseases. Allergol Int 2008; 57: 291-298.
26. 4 receptor-1 expression during neutrophilic differentiation of HL-60 cells. Biochem Biophys Res Comm 2003; 309: 114-119.
27. 4 receptor 1. J Allergy Clin Immunol 2008; 121: 864-871.
28. 3 phosphorylation by protein kinase A. J Biol Chem 1998; 273: 11012-11016.
29. 3 receptor. Respir Res 2006; 7: 34.
30. Anderson R, Visser SS, Ramafi G, et al. Accelerated resequestration of cytosolic calcium and suppression of the pro-inflammatory activities of human neutrophils by CGS 21680. Br J Pharmacol 2000; 130: 717-724.
31. Flamand N, Surette ME, Picard S, et al. Cyclic AMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils. Mol Pharmacol 2002; 62: 250-256.
32. 4. Clin Exp Immunol 2007; 150: 144-150.